8-K: Surgery Partners Announces Strong Q1 2025 Results and Reaffirms Full-Year Guidance

Surgery Partners reports an 8.2% increase in revenue and reaffirms its full-year 2025 revenue and Adjusted EBITDA guidance.

Summary

• Surgery Partners announced its first quarter 2025 results, showing an 8.2% increase in revenue to $776.0 million compared to $717.4 million in Q1 2024.
• Same-facility revenues increased by 5.2%, driven by a 6.5% increase in same-facility cases, although revenue per case decreased by 1.2%.
• The company reported a net loss attributable to Surgery Partners, Inc. of $37.7 million for the quarter.
• Adjusted EBITDA increased by 6.6% to $103.9 million.
• Surgery Partners reaffirmed its full-year 2025 revenue guidance to be in the range of $3.30 billion to $3.45 billion and Adjusted EBITDA guidance to be in the range of $555 million to $565 million.
• As of March 31, 2025, the company had $229.3 million in cash and cash equivalents and $388.9 million of borrowing capacity under its revolving credit facility.
• Cash flows from operating activities were $6.0 million for the first quarter of 2025, compared to $40.7 million for the same period in 2024, with the change due to the timing of routine transactions involving working capital.
• The company's ratio of total net debt to EBITDA was approximately 4.1x at the end of the first quarter of 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to revenue growth, reaffirmed guidance, and sufficient liquidity, although a net loss tempers the overall outlook.

Positives

• Revenue increased by 8.2% year-over-year.
• Same-facility revenues increased by 5.2%.
• Adjusted EBITDA increased by 6.6%.
• Full-year guidance for revenue and Adjusted EBITDA was reaffirmed.
• The company has sufficient liquidity to fund future M&A activity without needing to access incremental capital from debt or equity markets over the next five years.

Negatives

• The company reported a net loss attributable to Surgery Partners, Inc. of $37.7 million for the first quarter.
• Cash flows from operating activities decreased to $6.0 million from $40.7 million in the same period last year, due to timing of routine transactions involving working capital.
• Revenue per case decreased by 1.2%.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially.
• These risks include reductions in payments from government health care programs and private insurance payors, the ability to contract with private insurance payors, changes in payor mix or surgical case mix, and failure to maintain or develop relationships with physicians.
• Other risks include supply chain issues, competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts, the ability to attract and retain qualified health care professionals, and the impact of future legislation and other health care regulatory reform actions.

Future Outlook

The company reaffirmed its full-year 2025 revenue guidance to be in the range of $3.30 billion to $3.45 billion and Adjusted EBITDA guidance to be in the range of $555 million to $565 million.

Management Comments

• Eric Evans, CEO, stated that the company continues to deliver growth consistent with its long-term growth algorithm.
• Dave Doherty, CFO, commented that the results are aligned with internal expectations and give increased confidence in reaffirming full-year guidance.
• Dave Doherty, CFO, stated that the company has sufficient liquidity to fund future M&A activity without needing to access incremental capital from the debt or equity markets over the next five years.

Industry Context

Surgery Partners operates in the short-stay surgical facility market, which is benefiting from favorable surgical trends and a supportive regulatory landscape. The company's focus on maximizing portfolio performance, M&A, and operating efficiencies positions it to deliver industry-leading earnings growth.

Comparison to Industry Standards

• Without specific industry benchmarks provided in the document, a comparison to industry standards is difficult.
• However, companies like AmSurg and United Surgical Partners International (USPI) are major players in the ambulatory surgery center (ASC) market.
• Surgery Partners' growth and profitability metrics would typically be compared against these and other similar companies to assess its relative performance.
• For example, HCA Healthcare, which also operates ASCs, could be used as a benchmark for operational efficiency and financial performance.

Stakeholder Impact

• Shareholders can expect continued growth and profitability, as indicated by the reaffirmed guidance.
• Employees can anticipate stability and potential opportunities for advancement within the growing company.
• Patients should benefit from the company's focus on providing high-quality, cost-effective surgical solutions.
• Physicians can expect continued support and partnership opportunities.
• Creditors can be reassured by the company's strong liquidity and manageable debt levels.

Next Steps

• Surgery Partners will hold a conference call on May 12, 2025, to discuss the results.
• The company will continue to focus on maximizing portfolio performance, advancing its M&A pipeline, and driving greater operating efficiencies.

Key Dates

Keywords

Surgery Partners, financial results, Adjusted EBITDA, revenue, surgical facilities, healthcare, M&A, guidance